CVKD · Cadrenal Therapeutics, Inc. Common Stock

Summary

Cadrenal Therapeutics, Inc. issued a press release on March 12, 2026, highlighting pre-clinical research demonstrating the potential of its first-in-class 12-LO product candidate. The press release is furnished as Exhibit 99.1 and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act.

Key takeaways

• Press release issued on March 12, 2026
• Highlights pre-clinical research on first-in-class 12-LO product candidate
• Furnished as Exhibit 99.1 under Item 7.01
• Not deemed 'filed' under Section 18
• Disclosed under Item 8.01 Other Events